Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection

Autor: Gail V. Matthews, Sanjay Bhagani, Marc Van der Valk, Juergen Rockstroh, Jordan J. Feld, Andri Rauch, Christine Thurnheer, Julie Bruneau, Arthur Kim, Margaret Hellard, David Shaw, Ed Gane, Mark Nelson, Patrick Ingiliz, Tanya L. Applegate, Jason Grebely, Phillipa Marks, Marianne Martinello, Kathy Petoumenos, Gregory J. Dore, Marc van der Valk, Greg Dore, Pip Marks, Gail Matthews, Tanya Applegate, Jordan Feld, Jürgen Rockstroh, Sophia Amjad, Elise Tu, Mahshid Tamaddoni, Maria Christine Thurnheer, Yvonne Gilleece, Chris Fraser, Alberto Moriggia, Thomas Lutz, Juhi Moon, Phillip Read, Arthur Y. Kim, Andrew Ustianowski, Christiane Cordes, Joe Sasadeusz, Mark Hull, Dominique Braun

Publikováno v: Matthews, Gail V; Bhagani, Sanjay; Van der Valk, Marc; Rockstroh, Juergen; Feld, Jordan J; Rauch, Andri; Thurnheer, Christine; Bruneau, Julie; Kim, Arthur; Hellard, Margaret; Shaw, David; Gane, Ed; Nelson, Mark; Ingiliz, Patrick; Applegate, Tanya L; Grebely, Jason; Marks, Phillipa; Martinello, Marianne; Petoumenos, Kathy; Dore, Gregory J; ... (2021). Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. Journal of hepatology, 75(4), pp. 829-839. Elsevier 10.1016/j.jhep.2021.04.056
J Hepatol
Journal of hepatology, 75(4), 829-839. Elsevier

Background & Aims Shortened duration therapy for acute and recent HCV infection has been shown to be highly effective in several small non-randomised studies with direct-acting antiviral regimens; however, large randomised studies are lacking. Method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56cb0f6e8b73a263af7310a4cfd284e8
https://boris.unibe.ch/156581/1/1-s2.0-S0168827821003366-main.pdf

Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy

Autor: Amanda Erratt, Jordan J. Feld, Curtis Cooper, Gail V. Matthews, Sione Crawford, Adrian Dunlop, David R. Shaw, Catherine A.M. Stedman, Kathy Petoumenos, Tanya L. Applegate, Margaret Hellard, Phillipa Marks, Brian Conway, Erika Castro, Alberto Moriggia, Evan B Cunningham, Jeff Powis, Ian Kronborg, Gregory J. Dore, Patrick Schmid, Edward Gane, Christopher S. Fraser, Julie Bruneau, Olav Dalgard, Jean-Pierre Daulouède, Karine Lacombe, Jason Grebely, Philip Bruggmann, Behzad Hajarizadeh

Publikováno v: International Journal of Drug Policy. 62:94-103

Background: Direct-acting antiviral therapy for hepatitis C virus (HCV) infection is safe and effective, but there are little data among people who have recently injected drugs. This study evaluated the efficacy, and safety of paritaprevir/ritonavir,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91ed53cf823d3bc23d54c91273597287
https://doi.org/10.1016/j.drugpo.2018.10.004

Can Spectrum Trading and Pricing Co-Exist?

Autor: Phillipa Marks, Brian Williamson

Publikováno v: SSRN Electronic Journal.

There have been moves towards greater reliance on market mechanisms for spectrum management – auctions, trading, private band management and leasing – in North America, the EU and a number of other countries. Alongside these developments, regulat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ae0ced37f35876dbe2b38948044886f9
https://doi.org/10.2139/ssrn.1739107

Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

Autor: William D. Rawlinson, Vijayaprakash Suppiah, Gail V. Matthews, Tanya L. Applegate, Andrew R. Lloyd, Jacob George, David R. Booth, Gregory J. Dore, John M. Kaldor, Margaret Hellard, Kathy Petoumenos, Phillipa Marks, Jason Grebely, Barbara Yeung

Polymorphisms in the IL28B (interleukin-28B) gene region are important in predicting outcome following therapy for chronic hepatitis C virus (HCV) infection. We evaluated the role of IL28B in spontaneous and treatment-induced clearance following rece

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28d94d4c62b7f2ea2b8cdeb7ddc86a31
https://hdl.handle.net/1959.8/155321

Internet Driven Convergence - Policy Implications

Autor: Phillipa Marks, Brian Williamson

Publikováno v: SSRN Electronic Journal.

Digital content, Internet Protocol (IP), Moore’s law and a move from dedicated hardware to software based systems and rights management are enabling convergence. Convergence can be thought of as occurring in three phases. In the first phase of conv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::410ded34788db4f08da62e0e994dc2e2
https://doi.org/10.2139/ssrn.1518571